25 May,2021 02:50 PM IST | Mumbai | PTI
Maharashtra Health Minister Rajesh Tope
Maharashtra Health Minister Rajesh Tope on Tuesday said the state would get 60,000 vials of Amphotericin-B, the key drug for the treatment of mucormycosis patients, from June 1 onwards.
There are 2,245 patients of mucormycosis, also known as the black fungus, in Maharashtra, Tope told reporters after attending a review meeting on the mucormycosis and Covid-19 cases in the state.
Tope said the state has floated a global tender for procuring Amphotericin-B vials for the treatment of mucormycosis. "The state would get 60,000 vials of the medicine from June 1 onwards. It will be an additional supply apart from the current allocation of the medicine by the Centre," he said.
Also Read: Maharashtra govt declares Mucormycosis as notifiable disease
ALSO READ
Bengaluru: Case registered in connection with COVID-19 mismanagement
Biden commutes roughly 1,500 sentences, pardons 39
Morocco produces Africa’s first test kits to fight Mpox
Covid virus lurks in skull and brain meninges for years after infection: Study
‘Misguided, forced to take Covid vaccines’
The minister said there are 2,245 patients of black fungus in the state and out of them, 1,007 are already covered under the Mahatma Jyotirao Phule Jan Arogya Yojana (MJPJAY), he said.
"The entire cost of the treatment of mucormycosis patients under the MJPJAY will be free of cost, including the cost of the medicine. The state is also trying to cap the cost of treatment of mucormycosis patients who are admitted in private hospitals," he said.
Tope said the Maharashtra government has issued a GR (government resolution) regarding such treatment and the finance department has allocated Rs 30 crore for the same.
There have been several cases of mucormycosis, a rare but serious fungal infection, among Covid-19 patients in Maharashtra and some other states.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.